Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Eflornithine + Etoposide |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Eflornithine | Iwilfin | DFMO|alpha-difluoromethylornithine | Iwilfin (eflornithine) is an ornithine decarboxylase inhibitor that blocks polyamine production, resulting in reduced tumor cell proliferation (PMID: 32256343). Iwilfin (eflornithine) is FDA-approved for use in adult and pediatric patients with high-risk neuroblastoma who have responded to prior therapies (FDA.gov) | |
Etoposide | Vepesid | EPEG|Eposin|VP-16|VP-16-213 | TOPO2 inhibitor 5 | Vepesid (etoposide) binds to and inhibits DNA topoisomerase II, resulting in accumulated DNA damage, inhibition of replication, and cell death (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04301843 | Phase II | Eflornithine + Etoposide | Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma | Recruiting | USA | CAN | 0 |